Another clinical trial (ClinicalTrials.gov identifier NTC01267422) in which nine patients affected by LHON carrying the G11778A mutation were treated with a single dose (5 × 109 vg/0.05 mL) of rAAV2-ND4 reported no adverse effects. This evidence concerns the gene MT-ND4 and Leber hereditary optic neuropathy.